(00022): Chen Hui En appointed as authorized representative
Melco International Development Limited (00022) announced that Mr. Yau Chi Kin (Mr. Yau) has resigned as the Chairman of the Company, an Executive Director of the Company, an authorized representative of the Company under Rule 3.05 of the Listing Rules, the Chairman of the Executive Committee, the Chairman of the Nomination Committee, and a member of the Remuneration Committee of the Company, with effect from July 22, 2026, in order to focus on other business arrangements.
Announcement: Mr. Lun Yao-ji (Mr. Lun) has resigned from his positions as Chairman of the Company, Executive Director of the Company, authorized representative of the Company under Rule 3.05 of the Securities Listing Rules, Chairman of the Executive Committee of the Company, Chairman of the Nomination Committee of the Company, and member of the Remuneration Committee of the Company, with effect from July 22, 2026.
Following Mr. Lun's resignation, Ms. Chan Wai-yan, an independent non-executive director, has been appointed as the authorized representative of the Company, with effect from July 22, 2026.
After Mr. Lun's resignation, there have been the following changes to the board of directors: Mr. Lo Hok-yu, an executive director, has been reassigned as Chairman of the Executive Committee; and Ms. Li Jing-yi, an independent non-executive director, has been reassigned as Chairman of the Nomination Committee, with effect from July 22, 2026.
Related Articles

On July 22nd, GME Group (08188) spent HK$121,000 to buy back 100,000 shares.

CHINA NEW HLDGS (08125) plans to offer approximately 14.4% of its shares for sale, with a maximum of 20.68 million shares available. The net proceeds are expected to be around HKD 7.41 million.

CSTONE PHARMA-B (02616) obtained the director Yang Jianxin and senior management to increase their holdings by 2.42 million shares.
On July 22nd, GME Group (08188) spent HK$121,000 to buy back 100,000 shares.

CHINA NEW HLDGS (08125) plans to offer approximately 14.4% of its shares for sale, with a maximum of 20.68 million shares available. The net proceeds are expected to be around HKD 7.41 million.

CSTONE PHARMA-B (02616) obtained the director Yang Jianxin and senior management to increase their holdings by 2.42 million shares.

RECOMMEND





